271 related articles for article (PubMed ID: 32065006)
1. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
Meuth SG; Henze T; Essner U; Trompke C; Vila Silván C
Int J Neurosci; 2020 Dec; 130(12):1199-1205. PubMed ID: 32065006
[No Abstract] [Full Text] [Related]
2. Sativex
Markovà J; Essner U; Akmaz B; Marinelli M; Trompke C; Lentschat A; Vila C
Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
[TBL] [Abstract][Full Text] [Related]
3. Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from randomized clinical trials.
Marková J
Neurodegener Dis Manag; 2019 Apr; 9(2s):9-13. PubMed ID: 30657024
[TBL] [Abstract][Full Text] [Related]
4. Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
Mallada Frechín J
Neurodegener Dis Manag; 2018 Jun; 8(3):151-159. PubMed ID: 29851356
[TBL] [Abstract][Full Text] [Related]
5. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
Haupts M; Vila C; Jonas A; Witte K; Álvarez-Ossorio L
Eur Neurol; 2016; 75(5-6):236-43. PubMed ID: 27160412
[TBL] [Abstract][Full Text] [Related]
6. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
Vermersch P; Trojano M
Eur Neurol; 2016; 76(5-6):216-226. PubMed ID: 27732980
[TBL] [Abstract][Full Text] [Related]
7. Long-term assessment of the cognitive effects of nabiximols in patients with multiple sclerosis: A pilot study.
Alessandria G; Meli R; Infante MT; Vestito L; Capello E; Bandini F
Clin Neurol Neurosurg; 2020 Sep; 196():105990. PubMed ID: 32526487
[TBL] [Abstract][Full Text] [Related]
8. Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience.
D'hooghe M; Willekens B; Delvaux V; D'haeseleer M; Guillaume D; Laureys G; Nagels G; Vanderdonckt P; Van Pesch V; Popescu V
BMC Neurol; 2021 Jun; 21(1):227. PubMed ID: 34157999
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.
Paolicelli D; Direnzo V; Manni A; D'Onghia M; Tortorella C; Zoccolella S; Di Lecce V; Iaffaldano A; Trojano M
J Clin Pharmacol; 2016 Jul; 56(7):845-51. PubMed ID: 26608223
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.
Langford RM; Mares J; Novotna A; Vachova M; Novakova I; Notcutt W; Ratcliffe S
J Neurol; 2013 Apr; 260(4):984-97. PubMed ID: 23180178
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: Treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials.
Nicholas J; Lublin F; Klineova S; Berwaerts J; Chinnapongse R; Checketts D; Javaid S; Steinerman JR
Mult Scler Relat Disord; 2023 Jul; 75():104745. PubMed ID: 37209500
[TBL] [Abstract][Full Text] [Related]
12. Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes.
Di Marzo V; Centonze D
CNS Neurosci Ther; 2015 Mar; 21(3):215-21. PubMed ID: 25475413
[TBL] [Abstract][Full Text] [Related]
13. Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies.
Patti F
Neurodegener Dis Manag; 2019 Apr; 9(2s):3-7. PubMed ID: 30657027
[TBL] [Abstract][Full Text] [Related]
14. The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray).
Grimaldi AE; De Giglio L; Haggiag S; Bianco A; Cortese A; Crisafulli SG; Monteleone F; Marfia G; Prosperini L; Galgani S; Mirabella M; Centonze D; Pozzilli C; Castelli L
PLoS One; 2019; 14(7):e0219670. PubMed ID: 31361750
[TBL] [Abstract][Full Text] [Related]
15. Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence.
Ziemssen T
Neurodegener Dis Manag; 2019 Apr; 9(2s):1-2. PubMed ID: 30657019
[TBL] [Abstract][Full Text] [Related]
16. Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice.
Flachenecker P; Henze T; Zettl UK
Eur Neurol; 2014; 72(1-2):95-102. PubMed ID: 24943098
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.
Koehler J; Feneberg W; Meier M; Pöllmann W
Int J Neurosci; 2014 Sep; 124(9):652-6. PubMed ID: 24392812
[TBL] [Abstract][Full Text] [Related]
18. Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.
Contin M; Mancinelli L; Perrone A; Sabattini L; Mohamed S; Scandellari C; Foschi M; Vacchiano V; Lugaresi A; Riva R
Clin Neuropharmacol; 2018; 41(5):171-176. PubMed ID: 30024443
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study.
Trojano M; Vila C
Eur Neurol; 2015; 74(3-4):178-85. PubMed ID: 26571097
[TBL] [Abstract][Full Text] [Related]
20. A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
Arroyo González R
Expert Rev Neurother; 2018 Oct; 18(10):785-791. PubMed ID: 30235965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
